Chang, Yun
Cai, Xuechao
Syahirah, Ramizah http://orcid.org/0000-0003-2934-9655
Yao, Yuxing
Xu, Yang
Jin, Gyuhyung
Bhute, Vijesh J.
Torregrosa-Allen, Sandra
Elzey, Bennett D.
Won, You-Yeon http://orcid.org/0000-0002-8347-6375
Deng, Qing
Lian, Xiaojun Lance http://orcid.org/0000-0002-9161-1004
Wang, Xiaoguang http://orcid.org/0000-0002-4079-9596
Eniola-Adefeso, Omolola http://orcid.org/0000-0002-8728-6608
Bao, Xiaoping http://orcid.org/0000-0003-0955-6868
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R37CA265926)
Article History
Received: 1 November 2022
Accepted: 3 April 2023
First Online: 20 April 2023
Competing interests
: Y.C., R.S., Q.D., and X.B. are inventors on two patent applications (human chimeric antigen receptor neutrophils, compositions, kits and methods of use (WO2022125850A1), and blood-brain barrier-penetrating CAR-neutrophil-mediated drug delivery (provisional patent)) for content described in this manuscript. X.B. is an advisory chief scientific officer (CSO) for Astheneia Bio. The remaining authors declare no other competing interests.